Topoisomerase IIalpha-positive and BRCA1-negative phenotype: Association with favorable response to epirubicin-based regimens for human breast cancers

Cancer Letters

Volumn 264, Issue 1, 2008, Pages 44-53

  Miyoshi, Yasuo ^a   Kurosumi, Masafumi ^b   Kurebayashi, Junichi ^c   Matsuura, Nariaki ^d   Takahashi, Masato ^e   Tokunaga, Eriko ^f   Egawa, Chiyomi ^g   Masuda, Norikazu ^h   Kim, Seung Jin ^a   Okishiro, Masatsugu ^a   Yanagisawa, Tetsu ^a   Ueda, Satsuki ^a   Taguchi, Tetsuya ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d Tottori University   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

BRCA1; Breast cancer; Epirubicin; Pathological response; Topoisomerase IIalpha

Indexed keywords

BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DNA TOPOISMERASE IIALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GRADING; DNA STRAND BREAKAGE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BRCA1 PROTEIN; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PHENOTYPE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 42649141185     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.015     Document Type: Article

References (43)

1. French Epirubicin Study Group, A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin, J. Clin. Oncol. 6 (1988) 679-688.
2. Italian Multicentre Breast Study with Epirubicin, Phase III randomised study of fluorouracil, epirubicin and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide, in advanced breast cancer: an Italian Multicentre Trial, J. Clin. Oncol. 6 (1988) 976-982.
3. Penault-Llorca F., Cayre A., Bouchet Mishellany F., Amat S., Feillel V., Le Bouedec G., Ferriere J.P., De Latour M., and Chollet P. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int. J. Oncol. 22 (2003) 1319-1325
4. Veneroni S., Zaffaroni N., Daidone M.G., Benini E., Villa R., and Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur. J. Cancer 30 (1994) 1002-1007
5. Kandioler-Eckersberger D., Ludwig C., Rudas M., Kappel S., Janschek E., Wenzel C., Schlagbauer-Wadl H., Mittlbock M., Gnant M., Steger G., and Jakesz R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 6 (2000) 50-56
6. Ring A.E., Smith I.E., Ashley S., Fulford L.G., and Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 91 (2004) 2012-2017
7. Vincent-Salomon A., Rousseau A., Jouve M., Beuzeboc P., Sigal-Zafrani B., Freneaux P., Rosty C., Nos C., Campana F., Klijanienko J., Al Ghuzlan A., and Sastre-Garau X. Breast Cancer Study Group, Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur. J. Cancer 40 (2004) 1502-1508
8. Park K., Kim J., Lim S., and Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur. J. Cancer 39 (2003) 631-634
9. Pritchard K.I., Shepherd L.E., O'Malley F.P., Andrulis I.L., Tu D., Bramwell V.H., Levine M.N., and National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354 (2006) 2103-2111
10. Durbecq V., Desmed C., Paesmans M., Cardoso F., Di Leo A., Mano M., Rouas G., Leroy J.Y., Sotiriou C., Piccart M., and Larsimont A.D. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int. J. Oncol. 25 (2004) 1473-1479
11. Cardoso F., Durbecq V., Larsimont D., Paesmans M., Leroy J.Y., Rouas G., Sotiriou C., Renard N., Richard V., Piccart M.J., and Di Leo A. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int. J. Oncol. 24 (2004) 201-209
12. Jarvinen T.A., Tanner M., Rantanen V., Barlund M., Borg A., Grenman S., and Isola J. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156 (2000) 839-847
13. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65 (1996) 635-692
14. Cummings J., and Smyth J.F. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann. Oncol. 4 (1993) 533-543
15. Rudolph P., MacGrogan G., Bonichon F., Frahm S.O., de Mascarel I., Trojani M., Durand M., Avril A., Coindre J.M., and Parwaresch R. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res. Treat. 55 (1999) 61-71
16. Coon J.S., Marcus E., Gupta-Burt S., Seelig S., Jacobson K., Chen S., Renta V., Fronda G., and Preisler H.D. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 8 (2002) 1061-1067
17. Durbecq V., Paesmans M., Cardoso F., Desmedt C., Di Leo A., Chan S., Friedrichs K., Pinter T., Van Belle S., Murray E., Bodrogi I., Walpole E., Lesperance B., Korec S., Crown J., Simmonds P., Perren T.J., Leroy J.Y., Rouas G., Sotiriou C., Piccart M., and Larsimont D. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol. Cancer Ther. 3 (2004) 1207-1214
18. Bhargava R., Lal P., and Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am. J. Clin. Pathol. 123 (2005) 889-895
19. Fritz P., Cabrera C.M., Dippon J., Gerteis A., Simon W., Aulitzky W.E., and van der Kuip H. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res. 7 (2005) 374-384
20. Mueller R.E., Parkes R.K., Andrulis I., and O'Malley F.P. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39 (2004) 288-297
21. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., Schonau A., Gunnarsdóttir K., Olsen K.E., Mouridsen H., and Ejlertsen B. Danish Breast Cancer Cooperative Group: retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 23 (2005) 7483-7490 Erratum in, J. Clin. Oncol. 24 (2006) 1015
22. Di Leo A., Gancberg D., Larsimont D., Tanner M., Jarvinen T., Rouas G., Dolci S., Leroy J.Y., Paesmans M., Isola J., and Piccart M.J. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 8 (2002) 1107-1116
23. Scandinavian Breast Group Trial 9401. Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmström P., Wilking N., Nilsson J., and Bergh J. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24 (2006) 2428-2436
24. O'Malley F.P., Chia S., Tu D., Shepherd L.E., Levin M.N., Huntsman D.G., Bramwell V.H., Andrulis I.L., and Pritchard K.I. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). ASCO Proc. 24 18 Suppl. (2006) 11s
25. Zhong Q., Chen C.F., Li S., Chen Y., Wang C.C., Xiao J., Chen P.L., Sharp Z.D., and Lee W.H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285 (1999) 747-750
26. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., and Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22 (2003) 1169-1173
27. Sylvain V., Lafarge S., and Bignon Y.J. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int. J. Oncol. 20 (2002) 845-853
28. S. Delaloge, P. Pautier, I. Kloos, BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts, Paper presented at: 27th Congress of the European Society for Medical Oncology, Nice, France, 18-22 October, 2002, Abstract 120.
29. Miyamoto K., Fukutomi T., Asada K., Wakazono K., Tsuda H., Asahara T., Sugimura T., and Ushijima T. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn. J. Clin. Oncol. 32 (2002) 79-84
30. Baldassarre G., Battista S., Belletti B., Thakur S., Pentimalli F., Trapasso F., Fedele M., Pierantoni G., Croce C.M., and Fusco A. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell. Biol. 23 (2003) 2225-2238
31. Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K., Steele D., Savage K., Gillett C.E., Schmitt F.C., Ashworth A., and Tutt A.N. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2007) 2126-2132
32. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
33. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz Jr. A.B., Hoehn J.L., Lees A.W., Dimitrov N.V., and Bear H.D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16 (1998) 2672-2685
34. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., Theriault R.L., Singh G., Binkley S.M., Sneige N., Buchholz T.A., Ross M.I., McNeese M.D., Buzdar A.U., Hortobagyi G.N., and Singletary S.E. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17 (1999) 460-469
35. van der Hage J.A., van de Velde C.J., Julien J.P., Tubiana-Hulin M., Vandervelden C., and Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J. Clin. Oncol. 19 (2001) 4224-4237
36. The Journal of the Japanese Breast Cancer Society, General Rules for Clinical and Pathological Recording of Breast Cancer, Breast Cancer, Suppl. 12 (2005) 15.
37. Tsuda H., Sasano H., Akiyama F., Kurosumi M., Hasegawa T., Osamura R.Y., and Sakamoto G. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol. Int. 52 (2002) 126-134
38. Yang Q., Sakurai T., and Mori I. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 92 (2001) 54-60
39. Minisini A.M., Di Loreto C., Mansutti M., Artico D., Pizzolitto S., Piga A., and Puglisi F. Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett. 224 (2005) 133-139
40. MacGrogan G., Rudolph P., Mascarel Id I., Mauriac L., Durand M., Avril A., Dilhuydy J.M., Robert J., Mathoulin-Pélissier S., Picot V., Floquet A., Sierankowski G., and Coindre J.M. DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br. J. Cancer 89 (2003) 666-671
41. Arpino G., Ciocca D.R., Weiss H., Allred D.C., Daguerre P., Vargas-Roig L., Leuzzi M., Gago F., Elledge R., and Mohsin S.K. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res. Treat. 92 (2005) 69-75
42. Kalogeraki A., Ieromonachou P., Kafousi M., Giannikaki E., Vrekoussis T., Zoras O., Tsiftsis D., Delides G., and Stathopoulos E. Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables. In Vivo 19 (2005) 837-840
43. Meyer K.N., Kjeldsen E., Straub T., Knudsen B.R., Hickson I.D., Kikuchi A., Kreipe H., and Boege F. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J. Cell Biol. 136 (1997) 775-788